1. Home
  2. SLDB vs RDVT Comparison

SLDB vs RDVT Comparison

Compare SLDB & RDVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

N/A

Current Price

$8.29

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Logo Red Violet Inc.

RDVT

Red Violet Inc.

N/A

Current Price

$76.21

Market Cap

920.0M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
SLDB
RDVT
Founded
2013
2017
Country
United States
United States
Employees
121
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
932.9M
920.0M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
SLDB
RDVT
Price
$8.29
$76.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
1
Target Price
$16.36
$62.00
AVG Volume (30 Days)
825.9K
181.2K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
34.97
82.00
EPS
N/A
0.65
Revenue
$8,094,000.00
$90,252,000.00
Revenue This Year
N/A
$16.31
Revenue Next Year
N/A
$13.83
P/E Ratio
N/A
$117.25
Revenue Growth
N/A
20.03
52 Week Low
$3.79
$33.40
52 Week High
$11.45
$77.36

Technical Indicators

Market Signals
Indicator
SLDB
RDVT
Relative Strength Index (RSI) 37.66 60.32
Support Level $6.25 $51.66
Resistance Level $8.67 $77.36
Average True Range (ATR) 0.44 2.55
MACD -0.20 0.06
Stochastic Oscillator 9.05 74.78

Price Performance

Historical Comparison
SLDB
RDVT

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

About RDVT Red Violet Inc.

Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.

Share on Social Networks: